Xa因子抑制剂市场－全球产业规模、份额、趋势、机会、预测：按药物类型、给药途径、应用、地区和竞争格局划分，2021-2031年

全球 Xa 因子抑制剂市场预计将从 2025 年的 234.6 亿美元成长到 2031 年的 331.3 亿美元，复合年增长率为 5.92%。

凝血因子Xa是一种关键的丝胺酸蛋白酶，在凝血级联反应中负责合成凝血酶，是直接口服抗凝血剂（DOACs）的作用标靶，旨在预防和治疗血栓性栓塞症。该领域的发展主要受全球老年人口增长以及临床治疗从维生素K拮抗剂转向直接凝血因子Xa抑制剂的驱动。直接凝血因子Xa抑制剂因其更高的安全性以及便捷的固定剂量方案（可提高患者的用药依从性）而备受关注。

然而，出血不良事件的显着风险阻碍了市场发展，使治疗策略复杂化，并需要昂贵的逆转治疗。儘管存在这些障碍，凝血障碍在全球范围内造成的严重影响仍然凸显了对这些治疗方法的根本需求。根据国际血栓与止血学会（ISTH）的预测，到2024年，全球四分之一的死亡将由血栓症形成引起，这凸显了即使存在相关临床风险，对有效抗凝血治疗的迫切需求依然存在。

市场驱动因素

全球血栓性栓塞症和心血管疾病盛行率的上升是Xa因子抑制剂市场成长的主要驱动因素。中风和静脉血栓栓塞症发病率的增加推动了临床对直接作用Xa因子抑制剂作为标准预防性治疗的需求。这种沉重的疾病负担也反映在死亡率统计数据中；根据美国心臟协会（AHA）于2024年1月发布的《2024年心血管疾病和中风统计数据》，2021年全球约有1991万人死于心血管疾病。如此广泛的发病率正转化为主要行业参与者的可观收入。百时美施贵宝公司于2024年2月发布的《2023财年第四季及全年报告》显示，其艾乐妥（Eliquis）的全球销售额达到122亿美元，进一步证明了此类药物庞大的商业性规模。

同时，需要抗凝血治疗的老年人口迅速增长，推动了市场扩张。老龄化是心房颤动的主要危险因素，而长期抑制Xa因子是预防中风的必要措施。随着全球平均寿命的延长，符合治疗条件的患者数量增长速度超过了先前的预测。加州大学旧金山分校于2024年9月在《美国心臟病学会杂誌》上发表的一项研究表明，新的数据显示，美国将有1050万成年人受到心房颤动的影响，是先前估计的三倍。这一人口趋势必然导致患者群体扩大，而Xa因子抑制剂在老年人群中具有固定剂量和卓越的安全性，这促使医疗保健提供者优先考虑使用此类药物。

市场挑战

出血不良事件的风险是全球Xa因子抑制剂市场成长的主要障碍。口服抗凝血剂虽然对预防中风至关重要，但其可能导致严重出血，包括颅内出血和消化道出血，这引起了医疗专业人员的极大关注。这些安全问题需要严格的患者筛选和监测通讯协定，从而阻碍了市场发展，削弱了固定剂量给药方案的便利性。此外，治疗这些併发症和使用某些逆转剂的高昂费用也导致医生在处方方面犹豫不决，尤其是在医疗预算紧张的地区。

近期安全性数据凸显了这项临床挑战的严峻性。根据美国心臟协会 (AHA) 2024 年的报告，临床研究显示，在接受某些 Xa 因子抑制剂治疗的患者中，每 100 人年发生约 4.9 例大出血事件。这项统计数据强调了抗凝血治疗固有的不稳定性，并支持谨慎的处方策略，儘管凝血障碍十分普遍，但这种策略限制了市场的潜在成长。

市场趋势

随着主要药物专利到期，学名药的涌现正在从根本上改变Xa因子抑制剂市场。转向更经济实惠的替代药物降低了抗凝血治疗的经济门槛，并在预算紧张的医疗保健系统中扩大了患者的用药途径。近期生物等效替代药物的监管核准进一步凸显了这一趋势的强劲势头。正如《管理式医疗保健执行官》（Managed Healthcare Executive）2025年3月刊报导的《FDA核准首个非专利Xarelto》，美国食品药物管理局（FDA）核准了Lupin和Taro Pharmaceuticals等公司生产的首批2.5毫克Rivaroxaban药片学名药药。这标誌着该治疗领域定价结构的重大转变。

同时，某些逆转剂的商业化缓解了一个重要的安全隐患：与Xa因子抑制相关的无法控制的出血。诸如安德沙奈特α（andexanet alfa）等解毒剂的广泛应用，为临床医生提供了一种可靠的策略来应对危及生命的紧急情况，并增强了他们对处方直接口服抗凝剂而非维生素K拮抗剂的信心。关键逆转剂的财务成功也印证了这种对安全性治疗方法的需求。根据Astra Zeneca于2025年2月发布的2024财年年度报告和20-F表格信息，其逆转剂安德沙奈特α的全球销售额增长了20%，达到2.19亿美元，表明这些药物正迅速被纳入标准急救医疗通讯协定。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球Xa因子抑制剂市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 药物类型（直接Xa因子抑制剂、间接Xa因子抑制剂）
  • 给药途径（口服、注射）
  • 适应症（心房颤动、深层静脉栓塞症、肺动脉栓塞等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美Xa因子抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲Xa因子抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区Xa因子抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲地区Xa因子抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美因子Xa抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章 全球Xa因子抑制剂市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Bayer AG
• Pfizer Inc.
• Daiichi Sankyo Company, Limited
• Sanofi SA
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline plc
• Dr. Reddy's Laboratories Ltd.
• Mylan NV

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Factor Xa Inhibitors Market is projected to expand from USD 23.46 Billion in 2025 to USD 33.13 Billion by 2031, reflecting a compound annual growth rate of 5.92%. Factor Xa, a critical serine protease enzyme in the coagulation cascade that synthesizes thrombin, is the target for direct oral anticoagulants (DOACs) designed to prevent and treat thromboembolic conditions. Growth in this sector is largely fueled by a rising global geriatric population and a significant clinical shift away from vitamin K antagonists toward direct Factor Xa inhibitors, which are favored for their enhanced safety profiles and convenient fixed dosing regimens that improve patient compliance.

However, market advancement is hindered by the significant risk of adverse bleeding events, which complicates treatment strategies and necessitates expensive reversal agents. Despite this obstacle, the profound global impact of clotting disorders sustains underlying demand for these therapies. According to the International Society on Thrombosis and Haemostasis, thrombosis caused one in four deaths globally in 2024, highlighting the critical and ongoing need for effective anticoagulant treatments even amidst the associated clinical risks.

Market Driver

The rising global prevalence of thromboembolic and cardiovascular diseases acts as the primary engine for the Factor Xa Inhibitors Market's growth. With increasing rates of stroke and venous thromboembolism, the clinical demand for direct Factor Xa inhibitors as the standard preventative care has intensified. This heavy disease burden is reflected in mortality statistics; according to the American Heart Association's "Heart Disease and Stroke Statistics-2024 Update" from January 2024, cardiovascular disease caused roughly 19.91 million deaths worldwide in 2021. Such widespread prevalence translates into substantial revenue for major industry players, as evidenced by Bristol Myers Squibb's "Fourth Quarter and Full-Year Financial Results for 2023" report in February 2024, which announced $12.2 billion in global revenue for Eliquis, confirming the immense commercial magnitude of this drug class.

Concurrently, the rapid expansion of the aging population requiring anticoagulation therapy is boosting market development. Aging is a key risk factor for atrial fibrillation, a condition demanding chronic Factor Xa inhibition to prevent strokes. As global life expectancy increases, the number of eligible patients is surpassing previous estimates. According to a study published by the University of California San Francisco in the "Journal of the American College of Cardiology" in September 2024, new data suggests atrial fibrillation now impacts 10.5 million adults in the United States, a figure triple that of earlier projections. This demographic trend guarantees a widening patient base, urging healthcare providers to favor Factor Xa inhibitors due to their fixed dosing and superior safety profiles for older adults.

Market Challenge

The danger of adverse bleeding events serves as a major obstacle to the growth of the Global Factor Xa Inhibitors Market. Although direct oral anticoagulants are vital for stroke prevention, the possibility of severe hemorrhages, including intracranial or gastrointestinal bleeding, generates significant concern among medical professionals. These safety issues impede market progress by requiring strict patient selection and monitoring protocols, which diminish the convenience offered by fixed dosing schedules. Additionally, the high costs associated with managing these complications and utilizing specific reversal agents lead to prescribing hesitation, particularly in healthcare regions with strict budget constraints.

Recent safety data highlights the severity of this clinical challenge. According to the American Heart Association in 2024, clinical studies revealed that the incidence of major bleeding events in patients receiving specific Factor Xa inhibitors was approximately 4.9 per 100 person-years. This statistical proof emphasizes the inherent volatility of anticoagulant therapy, supporting a cautious prescribing approach that limits the market's potential growth trajectory despite the widespread prevalence of clotting disorders.

Market Trends

The introduction of generic formulations, spurred by recent patent expirations for major drugs, is fundamentally transforming the Factor Xa inhibitors sector. This shift toward more affordable alternatives is lowering the financial obstacles to anticoagulation therapy, thereby broadening patient access within budget-constrained healthcare systems. The strength of this trend is highlighted by recent regulatory approvals for bioequivalent options. As reported by Managed Healthcare Executive in the March 2025 article "FDA Approves First Generics of Xarelto," the U.S. Food and Drug Administration has cleared the first generic versions of rivaroxaban 2.5 mg tablets from manufacturers like Lupin and Taro Pharmaceuticals, signaling a major change in the pricing structure of this therapeutic category.

At the same time, the commercial availability of specific reversal agents is mitigating the critical safety concern of uncontrolled bleeding linked to Factor Xa inhibition. The growing use of antidotes such as andexanet alfa offers clinicians a dependable strategy for handling life-threatening emergencies, thereby bolstering confidence in the prescription of direct oral anticoagulants over vitamin K antagonists. This demand for safety-focused therapies is evident in the financial success of leading reversal agents. According to AstraZeneca's "Annual Report and Form 20-F Information 2024" released in February 2025, worldwide revenue for its reversal agent Andexxa increased by 20% to $219 million, demonstrating the rapid incorporation of these agents into standard emergency care protocols.

Key Market Players

• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Bayer AG
• Pfizer Inc.
• Daiichi Sankyo Company, Limited
• Sanofi S.A.
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline plc
• Dr. Reddy's Laboratories Ltd.
• Mylan N.V.

Report Scope

In this report, the Global Factor Xa Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Factor Xa Inhibitors Market, By Drug Type

• Direct Factor Xa Inhibitors
• Indirect Factor Xa Inhibitors

Factor Xa Inhibitors Market, By Route of Administration

• Oral
• Injectable

Factor Xa Inhibitors Market, By Application

• Atrial Fibrillation
• Deep Vein Thrombosis
• Pulmonary Embolism
• Others

Factor Xa Inhibitors Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Factor Xa Inhibitors Market.

Available Customizations:

Global Factor Xa Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Factor Xa Inhibitors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Direct Factor Xa Inhibitors, Indirect Factor Xa Inhibitors)
  • 5.2.2. By Route of Administration (Oral, Injectable)
  • 5.2.3. By Application (Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Factor Xa Inhibitors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Factor Xa Inhibitors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Factor Xa Inhibitors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Factor Xa Inhibitors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Application

7. Europe Factor Xa Inhibitors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Factor Xa Inhibitors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Application
  • 7.3.2. France Factor Xa Inhibitors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Factor Xa Inhibitors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Factor Xa Inhibitors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Factor Xa Inhibitors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Application

8. Asia Pacific Factor Xa Inhibitors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Factor Xa Inhibitors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Application
  • 8.3.2. India Factor Xa Inhibitors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Factor Xa Inhibitors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Factor Xa Inhibitors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Factor Xa Inhibitors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Application

9. Middle East & Africa Factor Xa Inhibitors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Factor Xa Inhibitors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE Factor Xa Inhibitors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa Factor Xa Inhibitors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Application

10. South America Factor Xa Inhibitors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Factor Xa Inhibitors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia Factor Xa Inhibitors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina Factor Xa Inhibitors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Factor Xa Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Teva Pharmaceutical Industries Ltd.
• 15.3. Bayer AG
• 15.4. Pfizer Inc.
• 15.5. Daiichi Sankyo Company, Limited
• 15.6. Sanofi S.A.
• 15.7. Boehringer Ingelheim International GmbH
• 15.8. GlaxoSmithKline plc
• 15.9. Dr. Reddy's Laboratories Ltd.
• 15.10. Mylan N.V.

16. Strategic Recommendations

17. About Us & Disclaimer